Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Effects of Teriparatide on Skeleton Images in Postmenopausal Women With Osteoporosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ambulatory with osteoporosis~* Hip or spine bone mineral density (BMD) measurement more than 2.5 standard deviations below the average bone mass of young healthy women or more than 2.0 standard deviations in women who have a history of a vertebral or nonvertebral fragility fracture.~Exclusion Criteria:~* Diseases of bone other than osteoporosis~* Treatment with estrogens in the 3 months prior to enrollment or for more than 2 months in the past year~* Treatment with oral bisphosphonates in the 3 months prior to enrollment or for more than 2 months in the past year; treatment with intravenous bisphosphonates in the 12 months prior to enrollment~* Increased risk for the development of osteosarcoma

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Teriparatide (Type: EXPERIMENTAL): Participants receive teriparatide 20 microgram once daily by subcutaneous injection for 18 months followed by 6 months off therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).